Clinical Trial Update: Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing cadonilimab as neoadjuvant therapy for resectable stage II-III colorectal cancer with MSI-H/dMMR.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: LiuYing | Conditions: Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Status: UNKNOWN